Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $19.00

Travere Therapeutics (NASDAQ:TVTX) had its price target hoisted by HC Wainwright from $17.00 to $19.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Travere Therapeutics’ FY2025 earnings at ($1.80) EPS, FY2026 earnings at $0.20 EPS, FY2027 earnings at $1.98 EPS and FY2028 earnings at $4.29 EPS.

Several other research firms also recently weighed in on TVTX. Guggenheim reissued a neutral rating on shares of Travere Therapeutics in a research note on Wednesday, March 27th. Wells Fargo & Company increased their price target on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an equal weight rating in a research note on Friday, February 16th. Wedbush reissued an outperform rating and issued a $13.00 price target on shares of Travere Therapeutics in a research note on Wednesday, April 17th. Finally, Piper Sandler upped their price objective on shares of Travere Therapeutics from $10.00 to $11.00 and gave the stock a neutral rating in a report on Thursday, January 18th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $18.00.

Travere Therapeutics Trading Down 2.4 %

NASDAQ:TVTX opened at $5.26 on Wednesday. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.41 and a current ratio of 3.47. The firm has a market cap of $400.33 million, a price-to-earnings ratio of -3.27 and a beta of 0.58. Travere Therapeutics has a 52 week low of $5.12 and a 52 week high of $22.75. The firm has a 50-day moving average price of $7.28 and a two-hundred day moving average price of $7.65.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.11. The company had revenue of $45.06 million during the quarter, compared to the consensus estimate of $41.25 million. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%. On average, equities analysts expect that Travere Therapeutics will post -3.1 earnings per share for the current fiscal year.

Insider Activity at Travere Therapeutics

In related news, SVP William E. Rote sold 4,764 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.71, for a total transaction of $41,494.44. Following the completion of the transaction, the senior vice president now directly owns 80,720 shares of the company’s stock, valued at $703,071.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Travere Therapeutics news, SVP William E. Rote sold 4,764 shares of Travere Therapeutics stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.71, for a total value of $41,494.44. Following the completion of the transaction, the senior vice president now directly owns 80,720 shares of the company’s stock, valued at approximately $703,071.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Eric M. Dube sold 19,122 shares of Travere Therapeutics stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $8.70, for a total transaction of $166,361.40. Following the completion of the transaction, the chief executive officer now directly owns 350,600 shares of the company’s stock, valued at $3,050,220. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,773 shares of company stock valued at $300,625. Corporate insiders own 3.75% of the company’s stock.

Hedge Funds Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TVTX. Armistice Capital LLC boosted its stake in shares of Travere Therapeutics by 0.7% during the 3rd quarter. Armistice Capital LLC now owns 7,500,000 shares of the company’s stock worth $67,050,000 after purchasing an additional 50,000 shares during the period. Vanguard Group Inc. raised its stake in Travere Therapeutics by 10.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,667,458 shares of the company’s stock worth $41,727,000 after acquiring an additional 460,176 shares during the last quarter. Kynam Capital Management LP raised its stake in Travere Therapeutics by 105.6% in the 4th quarter. Kynam Capital Management LP now owns 2,000,000 shares of the company’s stock worth $17,980,000 after acquiring an additional 1,027,398 shares during the last quarter. Jacobs Levy Equity Management Inc. raised its stake in shares of Travere Therapeutics by 9.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,671,770 shares of the company’s stock valued at $14,946,000 after buying an additional 146,970 shares during the last quarter. Finally, Finepoint Capital LP raised its stake in shares of Travere Therapeutics by 60.2% during the 4th quarter. Finepoint Capital LP now owns 1,435,321 shares of the company’s stock valued at $12,904,000 after buying an additional 539,500 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.